Abstract:Immunotherapy represented by programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies has led tumor treatment into a new era. However, the low overall response rate and high incidence of drug resistance largely damage the clinical benefits of existing immune checkpoint therapies. Recent studies correlate the response to PD-1/PD-L1 blockade with PD-L1 expression levels in tumor cells. Hence, identifying molecular targets and pathways controlling PD-L1 protein expression and stability in tumor cells is a major priority. In this study, we performed a Stress and Proteostasis CRISPR interference screening to identify PD-L1 positive modulators. Here, we identified TRAF6 as a critical regulator of PD-L1 in melanoma cells. As a non-conventional E3 ubiquitin ligase, TRAF6 is inclined to catalyze the synthesis and linkage of lysine-63 (K63) ubiquitin which is related to the stabilization of substrate proteins. Our results showed that suppression of TRAF6 expression down-regulates PD-L1 expression on the membrane surface of melanoma cells. We then used in vitro and in vivo assays to investigate the biological function and mechanism of TRAF6 and its downstream YAP1/TFCP2 signaling in melanoma. TRAF6 stabilizes YAP1 by K63 poly-ubiquitination modification, subsequently promoting the formation of YAP1/TFCP2 transcriptional complex and PD-L1 transcription. Inhibition of TRAF6 by Bortezomib enhanced cytolytic activity of CD8+ T cells by reduction of endogenous PD-L1. Notably, Bortezomib enhances anti-tumor immunity to an extent comparable to anti-PD-1 therapies with no obvious toxicity. Our findings reveal the potential of inhibiting TRAF6 to stimulate internal anti-tumor immunological effect for TRAF6-PD-L1 overexpressing cancers.

TRAF6 Regulates EGF-induced Cell Transformation and Cscc Malignant Phenotype Through CD147/EGFR

TRAF6 regulates tumour metastasis through EMT and CSC phenotypes in head and neck squamous cell carcinoma.

TRAF6 Promoted the Tumorigenicity of Esophageal Squamous Cell Carcinoma

TRAF6 Regulates Melanoma Invasion and Metastasis Through Ubiquitination of Basigin

TRAF6 Regulates YAP Signaling by Promoting the Ubiquitination and Degradation of MST1 in Pancreatic Cancer

TRAF6 Inhibits Colorectal Cancer Metastasis Through Regulating Selective Autophagic CTNNB1/β-catenin Degradation and is Targeted for GSK3B/GSK3β-mediated Phosphorylation and Degradation.

TRAF6 Activates Fibroblasts to Cancer-Associated Fibroblasts through FGF19 in Tumor Microenvironment to Benefit the Malignant Phenotype of Melanoma Cells

TRAF6 is Over-Expressed in Pancreatic Cancer and Promotes the Tumorigenicity of Pancreatic Cancer Cells

TSG-6 promotes Cancer Cell aggressiveness in a CD44-Dependent Manner and Reprograms Normal Fibroblasts to create a Pro-metastatic Microenvironment in Colorectal Cancer

Silencing CXCR6 Promotes Epithelial-Mesenchymal Transition and Invasion in Colorectal Cancer by Activating the VEGFA/PI3K/AKT/mTOR Pathway

Tumor Necrosis Factor Receptor-Associated Factor 6 Contributes to Malignant Behavior of Human Cancers Through Promoting AKT Ubiquitination and Phosphorylation

Tumor Necrosis Factor Receptor-associated Factor Family Protein 2 is a Key Mediator of the Epidermal Growth Factor-induced Ribosomal S6 Kinase 2/Camp-Responsive Element-binding Protein/Fos Protein Signaling Pathway*

TRAF6 promotes TGFβ-induced invasion and cell-cycle regulation via Lys63-linked polyubiquitination of Lys178 in TGFβ type I receptor

TRAF6 Regulates the Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Tumor-Bearing Host

TRAF6 is Upregulated in Colon Cancer and Promotes Proliferation of Colon Cancer Cells

Egf Potentiated Oncogenesis Requires A Tissue Transglutaminase-Dependent Signaling Pathway Leading To Src Activation

TRAF6 regulates the signaling pathway influencing colorectal cancer function through ubiquitination mechanisms

Increased expression of tumor necrosis factor receptor-associated factor 6 in pancreatic cancer and its clinical significance

High TRAF6 Expression is Associated with Esophageal Carcinoma Recurrence and Prompts Cancer Cell Invasion.

TRAF6 Enhances PD-L1 Expression Through YAP1-TFCP2 Signaling in Melanoma

TRAF6 regulates autophagy and apoptosis of melanoma cells through c-Jun/ATG16L2 signaling pathway